Evaluation of a pharmacist directed treat to target approach in patients with inflammatory bowel disease receiving upadacitinib or risankizumab
Crohn’s & Colitis 360 · 22.04.2026 · 8 (2)
DOI: 10.1093/crocol/otag026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Crohn’s & Colitis 360, online erschienen am 20.04.2026. Verfasst von Justin Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Chicago Medicine, Chicago, IL 60637, United States. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda.
Abstract (Originalsprache)
Background
An evolving strategy to enhance quality of life and remission rates in inflammatory bowel disease (IBD) is the treat-to-target approach. This approach offers a structured algorithm for therapeutic interventions, yet its implementation faces challenges, such as administrative burden and limited resources. This study elucidates the pharmacist’s role in the treat-to-target approach.
Methods
Retrospective chart review was conducted from August 7 to December 15, 2023. Patients ≥ 18 years of age, diagnosed with IBD, initiated on upadacitinib or risankizumab were included. “Treat-to-target” was defined as serial communication and monitoring of symptoms, clinical response, and laboratory values at predefined time points after starting therapy. A pharmacist-led follow-up protocol was conducted by an embedded IBD clinical pharmacist who assessed successful therapy initiation, medication adherence, steroid use, adverse effects, clinical disease activity, need for clinic visits, and lab monitoring at 2, 4, 8, 12 weeks, 6 months, and 12 months after therapy initiation.
Results
It was found that 227 patients initiated upadacitinib, and 210 initiated risankizumab. The overall success rate in reaching patients for through the pharmacist-directed follow-up protocol was 84%. The IBD Pharmacist made 3512 interventions, the most common being therapy continuation and lab monitoring recommendations. Therapy discontinuations were observed, particularly between 12 weeks and 6 months post-initiation.
Conclusions
We demonstrate a high participation rate to a pharmacist-led follow-up and monitoring protocol for patients receiving upadacitinib and risankizumab therapy. These findings underscore the importance of pharmacist-led interventions in ensuring continuity of care and tracking patient progress with IBD therapies, which are key elements of a successful treat-to-target strategy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, University of Chicago Medicine, Chicago, IL 60637, United States.
- Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL 60637, United States.
ORCID-Profile: Justin Han, David T Rubin, David K Choi
Förderung
- Takeda
Zitieren
APA
Han, J., Puangampai, A., Man, B., Kandah, H. M., Rubin, D. T., & Choi, D. K. (2026). Evaluation of a pharmacist directed treat to target approach in patients with inflammatory bowel disease receiving upadacitinib or risankizumab. Crohn’s & Colitis 360, 8(2). https://doi.org/10.1093/crocol/otag026
Vancouver
Han J, Puangampai A, Man B, Kandah HM, Rubin DT, Choi DK. Evaluation of a pharmacist directed treat to target approach in patients with inflammatory bowel disease receiving upadacitinib or risankizumab. Crohn’s & Colitis 360. 2026;8(2). doi:10.1093/crocol/otag026
BibTeX
@article{Han2026,
author = {Han, Justin and Puangampai, Archariya and Man, Bernice and Kandah, Huda-Marie and Rubin, David T and Choi, David K},
title = {Evaluation of a pharmacist directed treat to target approach in patients with inflammatory bowel disease receiving upadacitinib or risankizumab},
journal = {Crohn’s & Colitis 360},
year = {2026},
volume = {8},
number = {2},
doi = {10.1093/crocol/otag026}
}
EUVIMED